Head-to-head · Cost-Efficiency Index
FormBlends vs Ways2Well
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
FormBlends
Cost-first shoppers who want not applicable as a direct provider -- functions as a research/referral hub, not a prescriber.
Visit FormBlendsWays2Well
Patients wanting a broad, opaque-pricing concierge biomarker/longevity membership rather than a dedicated, transparently-priced GLP-1 program.
Visit Ways2WellThe verdict
FormBlends and Ways2Well tie on the Cost-Efficiency Index at 41/100, so neither wins outright on the numbers. For most shoppers we'd start with FormBlends (ranked #519, a hair above #524) — Cost-first shoppers who want not applicable as a direct provider -- functions as a research/referral hub, not a prescriber. But Ways2Well is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs FormBlends.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | FormBlends | Ways2Well |
|---|---|---|
| Cost-Efficiency Index | 41/100 | 41/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #519 | #524 |
FormBlends
41/100Where the value is
- Large self-reported provider directory (7,200+ profiles) and clinical research library
- Transparent about its own limitations, including an explicit pricing-may-be-stale disclaimer
- Claims 47-state coverage via its 503A pharmacy network of partner providers
The tradeoffs
- Not itself a licensed prescriber -- explicitly disclaims being a medical practice
- No verifiable direct pricing; site itself warns its listed provider prices may be outdated
Ways2Well
41/100Where the value is
- Backed by a known founder (Brigham Buhler) with an established functional-medicine brand
- Offers a broader diagnostic workup (100+ biomarkers, biannual panels) than typical single-purpose GLP-1 telehealth sites
- Confirms semaglutide/tirzepatide can be included in a custom protocol via a dedicated /semaglutide page
The tradeoffs
- No published GLP-1 pricing anywhere on the public site -- fully gated behind consultation/membership
- No published membership price either
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.